Company profile: Sirius Therapeutics
1.1 - Company Overview
Company description
- Provider of RNAi-based therapies for cardiovascular diseases, developing siRNA therapeutics including SRSD107 targeting coagulation Factor XI (FXI) for prevention and treatment of thromboembolic disorders with potential once- or twice-yearly dosing, and SRSD101 targeting PCSK9 to lower LDL-C for dyslipidemia; leveraging proprietary technology platforms and infrastructure in the US and China.
Products and services
- RNAi Therapeutics Development: Sirius Therapeutics engineers proprietary RNAi-based therapies for cardiovascular diseases, leveraging proprietary technology platforms and infrastructure in the US and China
- SRSD101: Sirius Therapeutics develops a siRNA-based therapeutic targeting PCSK9 to treat dyslipidemia, designed to lower LDL-C levels in the circulation
- SRSD107: Sirius Therapeutics produces an FXI-targeting siRNA therapeutic for prevention and treatment of thromboembolic disorders, with potential for once or twice-a-year dosing.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sirius Therapeutics
Portola Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics, discovering and developing treatments for acute and chronic cardiovascular and autoimmune/inflammatory diseases, including PRT054021, an oral factor Xa inhibitor for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Portola Pharmaceuticals company profile →
Spectranetics
HQ: United States
Website
- Description: Provider of excimer laser technology for minimally invasive cardiovascular procedures, marketing the only Excimer Laser System and offering a digital Instructions for Use Library with product manuals and usage guidance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spectranetics company profile →
NitroMed
HQ: United States
Website
- Description: Provider of proprietary nitric oxide-based pharmaceuticals, leveraging substantial expertise and intellectual property in nitric oxide drug development. The company discovers, develops, and seeks to commercialize therapies based on the therapeutic benefits of nitric oxide and is conducting a late-stage confirmatory trial of its lead nitric oxide-enhancing drug, BiDil.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NitroMed company profile →
FlowCardia
HQ: United States
Website
- Description: Provider of catheter-based medical device technologies that facilitate guidewire crossing and treatment of totally occluded coronary and peripheral arteries (Chronic Total Occlusions).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FlowCardia company profile →
Epix Therapeutics
HQ: United States
Website
- Description: Provider of microwave radiometry-based electrophysiology products that deliver real-time feedback on energy delivered by catheters during cardiac ablation procedures; develops, manufactures, and commercializes these solutions, with a strategic relationship with Hansen Medical Inc.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epix Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sirius Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sirius Therapeutics
2.2 - Growth funds investing in similar companies to Sirius Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sirius Therapeutics
4.2 - Public trading comparable groups for Sirius Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →